A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

Despite billions poured into research, new medicines still typically take a decade or more to develop.

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Shares of Bristol Myers Squibb Co. BMY dropped 0.08% to $59.22 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.56% to ...